Journal of Medicinal Chemistry
Article
lung cancer with mutated EGFR. N. Engl. J. Med. 2010, 362, 2380−
2388.
(5) Kobayashi, S.; Boggon, T. J.; Dayaram, T.; Jaenne, P. A.; Kocher,
O.; Meyerson, M.; Johnson, B. E.; Eck, M. J.; Tenen, D. G.; Halmos, B.
EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N. Engl. J. Med. 2005, 352, 786−792.
(6) Yun, C.; Mengwasser, K. E.; Toms, A. V.; Woo, M. S.; Greulich,
H.; Wong, K.; Meyerson, M.; Eck, M. J. The T790M mutation in
EGFR kinase causes drug resistance by increasing the affinity for ATP.
Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 2070−2075.
(7) Shepherd, F. A.; Pereira, J. R.; Ciuleanu, T.; Tan, E. H.; Hirsh, V.;
Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.;
Martins, R.; van Kooten, M.; Dediu, M.; Findlay, B.; Tu, D.; Johnston,
D.; Bezjk, A.; Clark, G.; Santabarbara, P.; Seymour, L. Erlotinib in
previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005,
353, 123−132.
(8) Zhang, Z.; Stiegler, A. L.; Boggon, T. J.; Kobayashi, S.; Halmos, B.
EGFR-mutated lung cancer: A paradigm of molecular oncology.
OncoTargets Ther. 2010, 1, 497−514.
(9) Sogabe, S.; Kawakita, Y.; Igaki, S.; Iwata, H.; Miki, H.; Cary, D.
R.; Takagi, T.; Takagi, S.; Ohta, Y.; Ishikawa, T. Structure-based
approach for the discovery of pyrrolo[3,2-d]pyrimidine-based EGFR
T790M/L858R mutant inhibitors. ACS Med. Chem. Lett 2013, 4, 201−
205.
(10) Gajiwala, K. S.; Feng, J.; Ferre, R.; Ryan, K.; Brodsky, O.;
Weinrich, S.; Kath, J. C.; Stewart, A. Insights into the aberrant activity
of mutant EGFR kinase domain and drug recognition. Structure
(Oxford, U. K.) 2013, 21, 209−219.
(11) Yun, C.; Woo, M. S.; Greulich, H.; Meyerson, M.; Eck, M. J.;
Wong, K. In Structural and mechanistic studies of lung cancer mutations
in the EGFR kinase reveal a novel mechanism of drug resistance, 236th
National Meeting of the American Chemical Society, Philadelphia, PA,
Aug 17−21, 2008; American Chemisal Society: Washington, DC,
2008; COMP 373.
(12) Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.;
Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P.
Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol.
2011, 29, 1046−1051.
(13) Yun, C.; Boggon, T. J.; Li, Y.; Woo, M. S.; Greulich, H.;
Meyerson, M.; Eck, M. J. Structures of lung cancer-derived EGFR
mutants and inhibitor complexes: Mechanism of activation and
insights into differential inhibitor sensitivity. Cancer Cell 2007, 11,
217−227.
(14) Lovly, C. M.; Horn, L. Strategies for overcoming EGFR
resistance in the treatment of advanced-stage NSCLC. Curr. Treat.
Options Oncol. 2012, 13, 516−526.
(15) Ou, S. I. Second-generation irreversible epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better
mousetrap? A review of the clinical evidence. Crit. Rev. Oncol. Hematol.
2012, 83, 407−421.
(16) Miller, V. A.; Hirsh, V.; Cadranel, J.; Chen, Y.; Park, K.; Kim, S.;
Zhou, C.; Su, W.; Wang, M.; Sun, Y.; Heo, D. S.; Crino, L.; Tan, E.;
Chao, T.; Shahidi, M.; Cong, X. J.; Lorence, R. M.; Yang, J. C. Afatinib
versus placebo for patients with advanced, metastatic non-small-cell
lung cancer after failure of erlotinib, gefitinib, or both, and one or two
lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial.
Lancet Oncol. 2012, 13, 528−538.
M. Targeting the EGFR pathway for cancer therapy. Curr. Med. Chem.
2006, 13, 3483−3492.
(20) Zhou, W.; Ercan, D.; Chen, L.; Yun, C.; Li, D.; Capelletti, M.;
Cortot, A. B.; Chirieac, L.; Iacob, R. E.; Padera, R.; Engen, J. R.; Wong,
K.; Eck, M. J.; Gray, N. S.; Janne, P. A. Novel mutant-selective EGFR
kinase inhibitors against EGFR T790M. Nature 2009, 462, 1070−
1074.
(21) Chang, S.; Zhang, L.; Xu, S.; Luo, J.; Lu, X.; Zhang, Z.; Xu, T.;
Liu, Y.; Tu, Z.; Xu, Y.; Ren, X.; Geng, M.; Ding, J.; Pei, D.; Ding, K.
Design, synthesis, and biological evaluation of novel conformationally
constrained inhibitors targeting epidermal growth factor receptor
threonine790 → methionine790 mutant. J. Med. Chem. 2012, 55,
2711−2723.
(22) Bai, F.; Liu, H.; Tong, L.; Zhou, W.; Liu, L.; Zhao, Z.; Liu, X.;
Jiang, H.; Wang, X.; Xie, H.; Li, H. Discovery of novel selective
inhibitors for EGFR-T790M/L858R. Bioorg. Med. Chem. Lett. 2012,
22, 1365−1370.
(23) Lee, H.; Schaefer, G.; Heffron, T. P.; Shao, L.; Ye, X.; Sideris, S.;
Malek, S.; Chan, E.; Merchant, M.; La, H.; Ubhayakar, S.; Yauch, R. L.;
Pirazzoli, V.; Politi, K.; Settleman, J. Noncovalent wild-type-sparing
inhibitors of EGFR T790M. Cancer Discovery 2013, 3, 168−181.
(24) Zhou, W.; Ercan, D.; Chen, L.; Yun, C.; Li, D.; Capelletti, M.;
Cortot, A. B.; Chirieac, L.; Iacob, R. E.; Padera, R.; Engen, J. R.; Wong,
K.; Eck, M. J.; Gray, N. S.; Janne, P. A. Novel mutant-selective EGFR
kinase inhibitors against EGFR T790M. Nature 2009, 462, 1070−
1074.
(26) Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. The resurgence
of covalent drugs. Nat. Rev. Drug Discovery 2011, 10, 307−317.
(27) Rauh, D. In Targeting protein kinases with irreversible inhibitors,
241st National Meeting of the American Chemical Society, Anaheim,
CA, March 27−31, 2011; American Chemical Society: Washington,
DC,2011; MEDI 157.
(28) Singh, J.; Evans, E.; Hagel, M.; Labinski, M.; Dubrovskiy, A.;
Nacht, M.; Petter, R. C.; Prasad, A.; Sheets, M.; StMartin, T.; Tjin
Tham Sjin, R.; Westlin, W.; Zhu, Z. Superiority of a novel EGFR
targeted covalent inhibitor over its reversible counterpart in over-
coming drug resistance. MedChemComm 2012, 3, 780−783.
(29) Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.;
Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.;
Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A new
approach for rapid, accurate docking and scoring. 1. Method and
assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739−1749.
(30) Ehmke, V.; Quinsaat, J. E. Q.; Rivera-Fuentes, P.; Heindl, C.;
Freymond, C.; Rottmann, M.; Brun, R.; Schirmeister, T.; Diederich, F.
Tuning and predicting biological affinity: Aryl nitriles as cysteine
protease inhibitors. Org. Biomol. Chem. 2012, 10, 5764−5768.
(32) Edwards, M. P.; Price, D. A. Role of physicochemical properties
and ligand lipophilicity efficiency in addressing drug safety risks. Annu.
Rep. Med. Chem. 2010, 45, 381−391.
(33) Leeson, P. D.; Springthorpe, B. The influence of drug-like
concepts on decision-making in medicinal chemistry. Nat. Rev. Drug
Discovery 2007, 6, 881−890.
(34) Leach, A. G.; Jones, H. D.; Cosgrove, D. A.; Kenny, P. W.;
Ruston, L.; MacFaul, P.; Wood, J. M.; Colclough, N.; Law, B. Matched
molecular pairs as a guide in the optimization of pharmaceutical
properties; a study of aqueous solubility, plasma protein binding and
oral exposure. J. Med. Chem . 2006, 49, 6672−6682.
(17) Allen, L. F.; Eiseman, I. A.; Fry, D. W.; Lenehan, P. F. CI-1033,
an irreversible pan-erbB receptor inhibitor and its potential application
for the treatment of breast cancer. Semin. Oncol. 2003, 30, 65−78.
(18) Kalous, O.; Conklin, D.; Desai, A. J.; O’Brien, N. A.; Ginther,
C.; Anderson, L.; Cohen, D. J.; Britten, C. D.; Taylor, I.; Christensen,
J. G.; Slamon, D. J.; Finn, R. S. Dacomitinib (PF-00299804), an
irreversible pan-HER inhibitor, inhibits proliferation of HER2-
amplified breast cancer cell lines resistant to Trastuzumab and
Lapatinib. Mol. Cancer Ther. 2012, 11, 1978−1987.
(35) Johnson, D. S.; Weerapana, E.; Cravatt, B. F. Strategies for
discovering and derisking covalent, irreversible enzyme inhibitors.
Future Med. Chem. 2010, 2, 949−964.
(36) Clarke, E. D.; Greenhow, D. T.; Adams, D. Metabolism-related
assays and their application to agrochemical research: Reactivity of
pesticides with glutathione and glutathione transferases. Pestic. Sci.
1998, 54, 385−393.
(37) MacFaul, P. A.; Morley, A. D.; Crawford, J. J. A simple in vitro
assay for assessing the reactivity of nitrile containing compounds.
Bioorg. Med. Chem. Lett. 2009, 19, 1136−1138.
(19) Johnston, J. B.; Navaratnam, S.; Pitz, M. W.; Maniate, J. M.;
Wiechec, E.; Baust, H.; Gingerich, J.; Skliris, G. P.; Murphy, L. C.; Los,
W
dx.doi.org/10.1021/jm400822z | J. Med. Chem. XXXX, XXX, XXX−XXX